\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesThe threats to cybersecurity increase continuously, affecting all systems managing data and information that might be interesting for intruders. The Funding & Tenders (F&T) Portal hosts a wealth of interesting information that might be under threat if users do not take the necessary measures.
Therefore the European Commission decided in Q4-2022 to increase the security and stimulate users to switch to using two-factor authentication (instead of the simple user name – password). A log-in as user is required in the F&T portal when you want to register as an organisation or to enter into the management of your proposal/project.
This switch to two-factor authentication requires limited effort. You have to register a mobile device, app or USB security key and activate the two-factor authentication. At each login, you will then be prompted for your usual password and for a second factor that is sent to your phone, app or you'll have to enter your USB key. A short video guides you through the installation. There also is an FAQ page available.
Currently two-factor authorisation is used by less than 1% of the users, but it is a priority for the EC to increase the usage level. On a practical note: if you are planning on switching to a new phone in the near future (e.g. before summer), we would advise you to wait until then to activate the 2 factor authentication. In any other case, there is no reason to postpone the activation of the extra verification step.
This is a revised version of a news item that was originally published on 2022-11-17.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The following call topics under the Digital Europe programme are now open for submission: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health EdTech Accelerator Digital Skills and Jobs Platform: The National Coalitions for Digi... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
